Acuros XB advanced dose calculation algorithm (AXB, Varian Medical Systems, Palo Alto, CA) has been released recently and provided the advantages of speed and accuracy for dose calculation. For clinical use, it is important to investigate the dosimetric performance of AXB compared to the calculation algorithm of the previous version, Anisotropic Analytical Algorithm (AAA, Varian Medical Systems, Palo Alto, CA). Ten volumetric modulated arc therapy (VMAT) plans for each of the following cases were included: head and neck (H&N), prostate, spine, and lung. The spine and lung cases were treated with stereotactic body radiation therapy (SBRT) technique. For all cases, the dose distributions were calculated using AAA and two dose reporting modes in AXB (dose-to-water, AXBw, and dose-to-medium, AXBm) with same plan parameters. For dosimetric evaluation, the dose-volumetric parameters were calculated for each planning target volume (PTV) and interested normal organs. The differences between AAA and AXB were statistically calculated with paired t-test. As a general trend, AXBw and AXBm showed dose underestimation as compared with AAA, which did not exceed within −3.5% and −4.5%, respectively. The maximum dose of PTV calculated by AXBw and AXBm was tended to be overestimated with the relative dose difference ranged from 1.6% to 4.6% for all cases. The absolute mean values of the relative dose differences were 1.1±1.2% and 2.0±1.2% when comparing between AAA and AXBw, and AAA and AXBm, respectively. For almost dose-volumetric parameters of PTV, the relative dose differences are statistically significant while there are no statistical significance for normal tissues. Both AXBw and AXBm was tended to underestimate dose for PTV and normal tissues compared to AAA. For analyzing two dose reporting modes in AXB, the dose distribution calculated by AXBw was similar to those of AAA when comparing the dose distributions between AAA and AXBm.
Introduction
Volumetric modulated arc therapy (VMAT) modulating the multi-leaf collimator (MLC) positions, gantry rotation speed, and dose rates has been broadly adopted in the clinic, having benefits of delivering prescription dose to target volume while sparing normal tissue. [1] [2] [3] It has shown that VMAT can achieve a similar plan quality and monitor unit (MU) effectiveness as compared to intensity modulated radiation therapy (IMRT) resulting in shortening the treatment time in the clinic. [4] [5] [6] As the portion of complicated radiotherapy technique such as VMAT increases in the clinic, demands on the accuracy and speed of dose calculation increases.
In 2010, Acuros XB advanced dose calculation algorithm (AXB, Varian Medical Systems, Palo Alto, CA) has been released as a clinical deterministic dose algorithm in the Eclipse treatment planning system (TPS) to meet accuracy and speed requirements for dose calculation. AXB uses the grid-based
Boltzmann solver (GBBS) to solve the Linear Boltzmann transport equation (LBTE) which describes the macroscopic behavior of radiation particles as they travel through and interact with matter. [7] [8] [9] Using the AXB, the radiation transport problem within small volumes could be solved to calculate dose distribution with accuracy and speed for dose calculation.
Several studies have demonstrated that the dose calculation from the AXB were very close to those from Monte carlo (MC) simulation compared to the widely used Anisotropic
Analytical Algorithm (AAA, Varian Medical Systems, Palo
Alto, CA) and Collapsed-con Convolution algorithm (CCC) in heterogeneous slab phantom. [10] [11] [12] It has been shown that there were similar findings from other groups in dose calculation involving high density volumes, 13) small field segments defined by MLC, 14) and RPC phantoms of head and neck (H&N) 15) and thorax. 16) For clinical cases, several studies have performed dosimetric comparison of VMAT and IMRT plans between AXB and AAA indicating that AXB underestimated the doses to targets or normal tissues in the cases of prostate, lung, H&N, and pelvis compared to AAA. [17] [18] [19] [20] In contrast to these results, other study has shown that AAA underestimated the dose in the cases of spine. 21) The difference between AXB and AAA depends on the treatment site and beam energy, which the results are patient-specific.
Depending on the energy dependent fluence-to-dose response function, AXB provides two dose reporting modes: dose-to-water (AXBw) and dose-to-medium (AXBm 
Materials and Methods

Patient selection
Among patients previously treated with VMAT technique in our institution, 10 patients for each prostate cancer, H&N cancer, spine cancer, and lung cancer were selected retrospectively for this study. The spine and lung cancers were treated with stereotactic body radiation therapy (SBRT) technique.
Planning and dose calculation
VMAT plans of all four cases of patients were generated in Medical Systems, Palo Alto, CA). To improve the dosimetric quality in VMAT plans, all VMAT plans were re-optimized using the current dose distribution as a reference for re-optimization. The dose distributions were calculated by using AAA. The calculation grid used in this study was 2.5 mm except for 1.0 mm for lung SBRT cases. Then, dose distributions were calculated by using AXBw and AXBm with same plan parameters following dose calculation using AAA. 
Analysis and evaluation of VMAT plans
For assessing the dosimetric quality with respect to PTV and normal organs, dose-volumetric histograms (DVHs) of AAA, AXBw, and AXBm were calculated in the Eclipse TPS.
The dose-volumetric parameters for PTV for all 4 clinical cases were the mean dose, maximum dose, minimum dose, D95%
(dose received by at least 95% volume), and D5%. For the normal organs, mean dose and D70% of rectum and bladder, maximum dose and D50% of left and right femur heads and kidneys, maximum dose of brain stem and optic chiasm, mean dose and V20 Gy (percent volume of the normal organ irradiated by at least 20 Gy) of left and right parotid glands, maximum dose and V13.5 Gy of spinal cord, maximum dose and V27.5 Gy of heart, and maximum dose and V20 Gy of left and right lungs were calculated. For a comparative purpose, the relative dose differences in the corresponding dose-volumetric parameters the AAA and AXB of the same case were calculated as follows 21) Relative dose difference (%)= 
Results
The dose-volumetric parameters of AAA, AXBw, and AXBm with respect to H&N, prostate, spine, and lung cases are shown in Tables 1, 2 AXBm, respectively. The Dn% (structure) means dose received n% volume of certain structure. Vn Gy (structure) means the percent volume of certain structure irradiated by at least n Gy. The minimum dose, maximum dose, and mean dose were abbreviated to min, max, and mean, respectively. The PTV, spinal cord, brain stem, optical chiasm, left parotid grand and right parotid grand were abbreviated to P, SC, BS, OC, PL and PR, respectively. respectively. The Dn% (structure) means dose received n% volume of certain structure. Vn Gy (structure) means the percent volume of certain structure irradiated by at least n Gy. The minimum dose, maximum dose, and mean dose were abbreviated to min, max, and mean, respectively. The PTV, rectum, bladder, left femur head and right femur head were abbreviated to P, R, B, FL and FR, respectively. respectively. The Dn% (structure) means dose received n% volume of certain structure. Vn Gy (structure) means the percent volume of certain structure irradiated by at least n Gy. The minimum dose, maximum dose, and mean dose were abbreviated to min, max, and mean, respectively. The PTV, left kidney and right kidney were abbreviated to P, KL and KR, respectively. respectively. The Dn% (structure) means dose received n% volume of certain structure. Vn Gy (structure) means the percent volume of certain structure irradiated by at least n Gy. The minimum dose, maximum dose, and mean dose were abbreviated to min, max, and mean, respectively. The PTV, spinal cord, heart, left lung, and right lung were abbreviated to P, SC, H, LL, and LR, respectively.
AXBw and AXBm, and maximum dose of brain stem from AXBw were overestimated with maximum value of the relative dose difference of 3.8%. For prostate cases which shows a similar tendency with H&N cases, the maximum value of the relative dose difference was −4.3% for D70% of rectum comparing AAA with AXBm while those was 4.0% for maximum dose of PTV comparing AAA with AXBw. In the case of spine, overestimation for AAA did not exceed within −4.5% compared with AXBm while maximum underestimation for AAA was 4.2% compared with AXBw. For lung cases, the maximum value of the relative dose difference was −2.8% for maximum dose of spinal cord comparing AAA with AXBm while those was 2.5% for maximum dose of PTV comparing AAA with AXBm. As a general trend, the relative dose differences comparing AAA and AXBw were tended to be smaller than those comparing AAA and AXBm for all 4 cases demonstrating that the absolute mean values of the relative dose differences were 1.1±1.2% and 2.0±1.2% when comparing between AAA and AXBw, and AAA and AXBm, respectively.
The averaged DVHs for AAA were shown to be very similar for normal tissue structures, but some notable differences in PTV compared against AXBw and AXBm.
Discussion
The dosimetric performance of AAA, AXBw, and AXBm was investigated for the H&N, prostate, spine, and lung cases.
The dosimetric evaluation was conducted regarding the results derived from the dose-volume parameters in the Eclipse TPS.
The preliminary results from the clinical cases in this study As shown in Figures 1, 2, 3 , and 4, the DVHs calculated by
AXBw was more matched with those of AAA for all cases in comparison with AXBm and AAA. For calculation procedure of AAA, last step to convert the absorbed energy distribution to a dose is scaling water materials using electron density instead of mass density. The report mode in AAA could be generally considered as dose-to-water mode supporting our findings. 31, 32) Selecting the appropriate dose reporting mode in the clinic is still debate. In 2003, Liu has asserted that dose-to-medium allows to provide a closer relationship between tissue response and dose while Keall has argued against this assertiveness and stated that all clinical experience and dosimetry protocols are based on the dose-to-water. 22) Further study is needed to determine the clinical impact depending on dose reporting modes in AXB.
Conclusion
In this study, the dose distributions calculated by AAA, AXBw, and AXBm were compared in all cases for H&N, prostate, spine, and lung for validating the performance of AXB.
Both AXBw and AXBm were tended to underestimate dose for PTV and normal tissues compared to AAA. For analyzing two dose reporting modes in AXB, the dose distribution calculated by AXBw was similar to those of AAA when comparing the dose distributions between AAA and AXBm.
